Cargando…
Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials?
BACKGROUND: The increasing number of clinical trials and their complexity make it challenging to detect and identify clinical quality issues timely. Despite extensive sponsor audit programs and monitoring activities, issues related to data integrity, safety, sponsor oversight and patient consent hav...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458946/ https://www.ncbi.nlm.nih.gov/pubmed/32865805 http://dx.doi.org/10.1007/s43441-020-00147-x |
_version_ | 1783576298035085312 |
---|---|
author | Koneswarakantha, Björn Ménard, Timothé Rolo, Donato Barmaz, Yves Bowling, Rich |
author_facet | Koneswarakantha, Björn Ménard, Timothé Rolo, Donato Barmaz, Yves Bowling, Rich |
author_sort | Koneswarakantha, Björn |
collection | PubMed |
description | BACKGROUND: The increasing number of clinical trials and their complexity make it challenging to detect and identify clinical quality issues timely. Despite extensive sponsor audit programs and monitoring activities, issues related to data integrity, safety, sponsor oversight and patient consent have recurring audit and inspection findings. Recent developments in data management and IT systems allow statistical modeling to provide insights to clinical Quality Assurance (QA) professionals to help mitigate some of the key clinical quality issues more holistically and efficiently. METHODS: We used findings from a curated data set from Roche/Genentech operational and quality assurance study data, covering a span of 8 years (2011–2018) and grouped them into 5 clinical impact factor categories, for which we modeled the risk with a logistic regression using hand crafted features. RESULTS: We were able to train 5 interpretable, cross-validated models with several distinguished risk factors, many of which confirmed field observations of our quality professionals. Our models were able to reliably predict a decrease in risk by 12–44%, with 2–8 coefficients each, despite a low signal-to-noise ratio in our data set. CONCLUSION: We proposed a modeling strategy that could provide insights to clinical QA professionals to help them mitigate key clinical quality issues (e.g., safety, consent, data integrity) in a more sustained data-driven way, thus turning the traditional reactive approach to a more proactive monitoring and alerting approach. Also, we are calling for cross-sponsors collaborations and data sharing to improve and further validate the use of statistical models in clinical QA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s43441-020-00147-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7458946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74589462020-09-11 Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? Koneswarakantha, Björn Ménard, Timothé Rolo, Donato Barmaz, Yves Bowling, Rich Ther Innov Regul Sci Original Research BACKGROUND: The increasing number of clinical trials and their complexity make it challenging to detect and identify clinical quality issues timely. Despite extensive sponsor audit programs and monitoring activities, issues related to data integrity, safety, sponsor oversight and patient consent have recurring audit and inspection findings. Recent developments in data management and IT systems allow statistical modeling to provide insights to clinical Quality Assurance (QA) professionals to help mitigate some of the key clinical quality issues more holistically and efficiently. METHODS: We used findings from a curated data set from Roche/Genentech operational and quality assurance study data, covering a span of 8 years (2011–2018) and grouped them into 5 clinical impact factor categories, for which we modeled the risk with a logistic regression using hand crafted features. RESULTS: We were able to train 5 interpretable, cross-validated models with several distinguished risk factors, many of which confirmed field observations of our quality professionals. Our models were able to reliably predict a decrease in risk by 12–44%, with 2–8 coefficients each, despite a low signal-to-noise ratio in our data set. CONCLUSION: We proposed a modeling strategy that could provide insights to clinical QA professionals to help them mitigate key clinical quality issues (e.g., safety, consent, data integrity) in a more sustained data-driven way, thus turning the traditional reactive approach to a more proactive monitoring and alerting approach. Also, we are calling for cross-sponsors collaborations and data sharing to improve and further validate the use of statistical models in clinical QA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s43441-020-00147-x) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-03-30 2020 /pmc/articles/PMC7458946/ /pubmed/32865805 http://dx.doi.org/10.1007/s43441-020-00147-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Koneswarakantha, Björn Ménard, Timothé Rolo, Donato Barmaz, Yves Bowling, Rich Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? |
title | Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? |
title_full | Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? |
title_fullStr | Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? |
title_full_unstemmed | Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? |
title_short | Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials? |
title_sort | harnessing the power of quality assurance data: can we use statistical modeling for quality risk assessment of clinical trials? |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458946/ https://www.ncbi.nlm.nih.gov/pubmed/32865805 http://dx.doi.org/10.1007/s43441-020-00147-x |
work_keys_str_mv | AT koneswarakanthabjorn harnessingthepowerofqualityassurancedatacanweusestatisticalmodelingforqualityriskassessmentofclinicaltrials AT menardtimothe harnessingthepowerofqualityassurancedatacanweusestatisticalmodelingforqualityriskassessmentofclinicaltrials AT rolodonato harnessingthepowerofqualityassurancedatacanweusestatisticalmodelingforqualityriskassessmentofclinicaltrials AT barmazyves harnessingthepowerofqualityassurancedatacanweusestatisticalmodelingforqualityriskassessmentofclinicaltrials AT bowlingrich harnessingthepowerofqualityassurancedatacanweusestatisticalmodelingforqualityriskassessmentofclinicaltrials |